Sinhagad Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-12-2024
- Paid Up Capital ₹ 0.75 M
as on 28-12-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 166.36%
(FY 2022)
- Profit 1769.84%
(FY 2022)
- Ebitda 97.04%
(FY 2022)
- Net Worth 44.00%
(FY 2022)
- Total Assets 14.45%
(FY 2022)
About Sinhagad Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.75 M, as per Ministry of Corporate Affairs (MCA) records.
Rahul Deshpande, Sanjay Shah, Sunil Dhorje, and Twelve other members serve as directors at the Company.
- CIN/LLPIN
U24290PN2020PTC193023
- Company No.
193023
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Aug 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sinhagad Pharma?
Board Members(15)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Deshpande  | Director | 17-Aug-2020 | Current |
| Sanjay Shah | Director | 17-Aug-2020 | Current |
| Sunil Dhorje | Director | 25-Aug-2020 | Current |
| Chetan Sharma | Director | 25-Aug-2020 | Current |
| Mangesh Karwa | Director | 25-Aug-2020 | Current |
| Sanjay Kunjeer | Director | 25-Aug-2020 | Current |
Financial Performance of Sinhagad Pharma.
Sinhagad Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 166.36% increase. The company also saw a substantial improvement in profitability, with a 1769.84% increase in profit. The company's net worth Soared by an impressive increase of 44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sinhagad Pharma?
Unlock access to Sinhagad Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Citycare Pharmacy LlpActive 2 years 7 months
Rahul Deshpande, Sanjay Shah and 11 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sinhagad Pharma?
Sinhagad Pharma has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sinhagad Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sinhagad Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
